Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(62)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 MXTDfZRwfG:6aXOgRZN{[Xl? NVu3c5pFOTBibl2= M3PXSlczKGh? NH3XdVBFVVOR NXTOeG9JWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NXfoeIY{OjR7MEC4O|M>
HT-29 MUfDfZRwfG:6aXOgRZN{[Xl? NVrpeZNwOTBibl2= NX7rTopTPzJiaB?= NFH1VnhFVVOR MofOVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 Mlu1NlQ6ODB6N{O=
HT-29 NXq3eXBPS3m2b4TvfIlkKEG|c3H5 M1PSV|ExKG6P M1HmV|czKGh? NXPsdWxETE2VTx?= MXPQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=> MkjVNlQ6ODB6N{O=
PC3 M{HR[WtqdmG|ZTDBd5NigQ>? MmHQNVAxKG6P MlThNUBp M17ybGROW09? MlXvVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= M2\VVFIyQTd6Nkiz
PC3 NXvUR3l4U2mwYYPlJGF{e2G7 NXXIem14OTByIH7N NIXvUIwyKGh? MWDEUXNQ NFzUT5NFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NYHWfY5tOjF7N{i2PFM>
PC3 MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfJdppyOS53IN88US=> M{LHXVEhcA>? NFHCWYtFVVOR MYrJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? NUe4O4wzOjF7N{i2PFM>
HEK293 NIDofXBHfW6ldHnvckBCe3OjeR?= M{XPdVExOCCwTR?= Mn62PEBp M3z3V2ROW09? NWfwdnBjUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N MYSyNVU{QTNyMR?=
BT-20 MofJT4lv[XOnIFHzd4F6 MnuxNlAh|ryP NIO0RYFFVVOR M3zkfmRw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w NXzrUGVrOjF|NUO1OVE>
U937 MUPBcpRq[mGldHXybYFtKEG|c3H5 M2HOelUxKM7:TR?= M3vxOFQ5KGh? MUPEUXNQ M1\YTGlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= NGro[HgzOTF2MkGwOi=>
U937 MlPDRY51cWKjY4TldolidCCDc4PhfS=> M4HvNlUxKM7:TR?= M{DGdVQ5KGh? MWDEUXNQ M4[3ZmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN? M{\LZVIyOTR{MUC2
U937 NEXLOXNCdnSrYnHjeIVzcWGuIFHzd4F6 MkfBOVAh|ryP NUTkV5AzPDhiaB?= MYLEUXNQ MlzaSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> NWqySJQzOjFzNEKxNFY>
MCF-7 NYT1TZhHSXW2b4DoZYd6KEG|c3H5 NEjlUZU{OCCwTR?= Mn;TOEBp MUjEUXNQ MUnJcoR2[2W|IHH1eI9xcGGpeR?= NHfTfJozODB{OEGzOC=>
U87MG NXfsRZZGU2mwYYPlJGF{e2G7 NWHMXYYyOSEQvF2= NVHOTIdxPiCq NXjIRolITE2VTx?= NVK0UFJnWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= NGrlRW8yQTh2OESwOC=>
U87MG NUnLPJRJU2mwYYPlJGF{e2G7 NFPYcFIyKM7:TR?= M{mwS|YhcA>? M33FO2ROW09? M3nmN3BwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u MmjVNVk5PDh2MES=
U87MG Mo[2T4lv[XOnIFHzd4F6 M4K3N|Eh|ryP MVK2JIg> MWPEUXNQ M{nGfWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NEDYV5UyQTh2OESwOC=>
U87MG MYfLbY5ie2ViQYPzZZk> NXzYUo5UOSEQvF2= M3nH[FYhcA>? NXTxWIZUTE2VTx?= NV\HTIZwTG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w M4DLVFE6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb M{HQWGF2fG:yaHHnfUBCe3OjeR?= Ml7pNE4zKM7:TR?= MWeyOEBp NWDK[YM1TE2VTx?= NH3FR|NKdmS3Y3XzJIF2fG:yaHHnfS=> M3qwZVE5OzlzOUS5
COS7 cells expressing EGFP-LC3 MWDBeZRweGijZ4mgRZN{[Xl? NYjqXGhPOC5{IN88US=> NVy0bGg4OjRiaB?= NWjoZYdETE2VTx?= M1rrcWlv\HWlZYOgZZV1d3CqYXf5 M1S0NlE5OzlzOUS5
H4 M2S5SmZ2dmO2aX;uJGF{e2G7 NH7FUoMxNjJizszN NUCx[JBiOjRiaB?= M2HKZmROW09? MUTJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz NYjUSWtmOThyMkS1PFQ>
HeLa MU\GeY5kfGmxbjDBd5NigQ>? NUfuZWlWOTByIH7N NXeyfZpDOzZiaB?= NFvrZ3VFVVOR NF;ae5pKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MVWxO|U3OzN6NR?=
HeLa MW\GeY5kfGmxbjDBd5NigQ>? M4W5bVExOCCwTR?= NH\zUIw{PiCq NED3OplFVVOR NVLQcWtjUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w M4HLZVE4PTZ|M{i1
HeLa NXLCWWtzTnWwY4Tpc44hSXO|YYm= Ml;vNVAxKG6P MlHIN|YhcA>? M3m2fGROW09? NEDIZWdKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> M{\S[VE4PTZ|M{i1
SYF NUHTUVVFTnWwY4Tpc44hSXO|YYm= NYnIXlJ3OTByIH7N MU[yOEBp M1HMSmROW09? MUTJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= M162[lE4PTZ|M{i1
SYF MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfLfphXOTByIH7N MUiyOEBp MkHKSG1UVw>? M13wOWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= NGqzclYyPzV4M{O4OS=>
HEK293T NVv6ToRiSW62aY\pdoFtKEG|c3H5 MYixJI5O MYG0JIQ> MU\EUXNQ MmHLTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= MVexO|Q5PTVyMR?=
HEK293T NWrvT4VYSW62aY\pdoFtKEG|c3H5 MkezNUBvVQ>? MV:0JIQ> MX\EUXNQ M4WwOWlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N NXvUOlRsOTd2OEW1NFE>
PBMC NFHQWIpHfW6ldHnvckBCe3OjeR?= MYexJI5O M{PBfFE1KGR? M{nGc2ROW09? MV3S[YR2[2W|IFPDVlUh\GWwc3n0fS=> M{DueVE4PDh3NUCx
PBMC M2PTSGZ2dmO2aX;uJGF{e2G7 NUTOUZlROSCwTR?= NHP4[ZgyPCCm NXzXXIdFTE2VTx?= M{TTdmRw\XNibn;0JIFn\mWldDDDXGNTPCCmZX7zbZR6 MoC1NVc1QDV3MEG=
HEK293 cells M3vXbGtqdmG|ZTDBd5NigQ>? NXXBO2dyPTBibl2= NYLoTm94PDVibXnu NYHZW4ZNTE2VTx?= M33wRmlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? NYXGUpltOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NWnXRlRUTnWwY4Tpc44hSXO|YYm= NV[wSplYOTByIH7N M3HU[lQhcA>? NEn4bHdFVVOR M1ezUmlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk Mkn4NVcyOjh{NkK=
Human mixed lymphocyte MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m1SFUhdk1? M{C5c2ROW09? NVGxPGJnUUN3ME2xMlYhdk1w NHPjTXEyPjF6NUi2OS=>
Lewis rat lymph node cells M4jwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjxOUDPxE1? NWK0eXllTE2VTx?= NVzFNXhVUUN3ME2yMlYh|ryP NUDHT4N{OTZzOEW4OlU>
cells from the thymus of normal BALB/c mice MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH3WngyOCCwTR?= MWS3NkBp MnP5SG1UVw>? MmPvTY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= NF\iXYYyODB{MUm0PC=>
MRK-nu-1 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwOES1JJBO M33zTXNCVkeHUh?=
OCUB-M Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvLW2VMUUN3ME21MlI1KHCP MUXTRW5ITVJ?
SF539 NWfENHpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFzLk[gdG0> Mnn2V2FPT0WU
ES4 NHLwSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJzLkWgdG0> NESyNWVUSU6JRWK=
RL95-2 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H3ZWlEPTB;MUC3JJBO MU\TRW5ITVJ?
LC-2-ad MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTOTWM2OD12MkOgdG0> M2nXbnNCVkeHUh?=
Daudi MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPGUmFKSzVyPUSzOEBxVQ>? MXLTRW5ITVJ?
NTERA-S-cl-D1 M3fPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR2MzDwUS=> NYTNXFA4W0GQR1XS
OS-RC-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\meJNKSzVyPU[1NkBxVQ>? NIS5SndUSU6JRWK=
VA-ES-BJ NXfVOXFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTd{MzDwUS=> NGLvfZpUSU6JRWK=
GR-ST MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXHb5FKSzVyPUi0OkBxVQ>? MYTTRW5ITVJ?
SW872 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnMTWM2OD16NE[gdG0> MoPNV2FPT0WU
NOS-1 NVPxOJFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TO[2lEPTB;OEexJJBO NXPENI5bW0GQR1XS
MC116 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fFdmlEPTB;OUi1JJBO NGn4SIhUSU6JRWK=
NCI-H1355 NGXMZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[3V3BlUUN3ME2xMlAyKG6P M1XNdXNCVkeHUh?=
RPMI-8226 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFwMUmgcm0> NIX6PXVUSU6JRWK=
TE-15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPiXJJmUUN3ME2xMlM3KG6P NWTTOW94W0GQR1XS
Ramos-2G6-4C10 NULmV2NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfGcI9LUUN3ME2xMlQ3KG6P NXLufW9{W0GQR1XS
KU812 M1\abmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjsWFdOUUN3ME2yMlAyKG6P MYPTRW5ITVJ?
EW-1 NHj6R2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ycmlKSzVyPUKuNVchdk1? MkP3V2FPT0WU
KS-1 M4\4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwNEWgcm0> NF3reHRUSU6JRWK=
SK-LMS-1 M{HYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrTUoZnUUN3ME2yMlQ6KG6P MoLoV2FPT0WU
TGBC1TKB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSxTWM2OD1{Lk[5JI5O M1zvWXNCVkeHUh?=
TE-6 M{TzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzhe4lpUUN3ME2yMlc4KG6P NVnYcW5TW0GQR1XS
ETK-1 NGPVOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLDdWpKSzVyPUKuPFIhdk1? MlK2V2FPT0WU
BE-13 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;1TWM2OD1{Lkm5JI5O MUHTRW5ITVJ?
A3-KAW MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJwOUmgcm0> MYnTRW5ITVJ?
TE-10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn1TWM2OD1|LkOgcm0> NFjXfXZUSU6JRWK=
DOHH-2 M1T4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m1eWlEPTB;Mz6zOUBvVQ>? MVnTRW5ITVJ?
ES6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3xUpRKSzVyPUOuOFMhdk1? MYrTRW5ITVJ?
OPM-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDzTWM2OD12LkG1JI5O Ml;nV2FPT0WU
SH-4 NVK2ZnRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LEZmlEPTB;ND6zOEBvVQ>? MkfSV2FPT0WU
NB13 M1fuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELqRZVKSzVyPUSuN|Yhdk1? M1PkZnNCVkeHUh?=
HUTU-80 M3fXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[y[mlEPTB;ND60NkBvVQ>? MoHRV2FPT0WU
CCRF-CEM M4CwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG3So1SUUN3ME20Mlk1KG6P MVjTRW5ITVJ?
TGBC24TKB NIrsXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nTUmlEPTB;NT61NUBvVQ>? NWHXU2VKW0GQR1XS
697 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPPTFNzUUN3ME22MlI5KG6P NYrLdVBnW0GQR1XS
J-RT3-T3-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy2fYJKSzVyPU[uOFYhdk1? NHrXU2FUSU6JRWK=
KALS-1 NGPYflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTZwNU[gcm0> MoHNV2FPT0WU
no-10 NYfqO5o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdwMkmgcm0> MoHFV2FPT0WU
SK-NEP-1 M3;RUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu5NIJmUUN3ME24Mlc6KG6P M4e4eHNCVkeHUh?=
L-540 NWT5V3gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDzbIdKSzVyPUGwMlQzKG6P NEjp[2ZUSU6JRWK=
JiyoyeP-2003 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHBTWM2OD1zMD65OEBvVQ>? MUjTRW5ITVJ?
HH MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v1e2lEPTB;MUGuN|khdk1? M1;hOHNCVkeHUh?=
SR NV[1Z2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzxTWM2OD1zMT60OUBvVQ>? MXvTRW5ITVJ?
QIMR-WIL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7zenhKSzVyPUGxMlg2KG6P MVvTRW5ITVJ?
A4-Fuk M4fJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH4TWM2OD1zMz6xNkBvVQ>? NXHOWpRYW0GQR1XS
CESS Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfaOVZKSzVyPUGzMlE{KG6P MX\TRW5ITVJ?
KE-37 NXXMZVY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnlTWM2OD1zNj6wO{BvVQ>? MUnTRW5ITVJ?
SK-UT-1 NEHQUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDZTWM2OD1zNj64NUBvVQ>? NF\hWo5USU6JRWK=
SIG-M5 NXf2XFFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDhW29KSzVyPUG3MlI2KG6P Mmj5V2FPT0WU
HT NYn2OmhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF5Lk[gcm0> MWjTRW5ITVJ?
DEL NUDteoEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XaUGlEPTB;MUeuPVkhdk1? M4rVSnNCVkeHUh?=
SK-PN-DW NHPhU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJyLkKzJI5O M4fvfHNCVkeHUh?=
RPMI-8402 M4G4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDJZ5lKSzVyPUKxMlc4KG6P MXPTRW5ITVJ?
RPMI-6666 NGHOcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;Sbod6UUN3ME2yOE41OiCwTR?= MkLaV2FPT0WU
NCI-H720 M2K1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ3LkSxJI5O M3ToZ3NCVkeHUh?=
EW-16 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO0VpdxUUN3ME2yOk45PyCwTR?= NULuPVh{W0GQR1XS
BL-70 M37yTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD1{OD6zPEBvVQ>? MXXTRW5ITVJ?
SF126 NY\ObVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTNyLkO4JI5O NYrTOGpoW0GQR1XS
BC-1 NIrGZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjIV|BKSzVyPUOxMlI3KG6P MVLTRW5ITVJ?
MHH-PREB-1 M1TUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnobIVwUUN3ME2zNk41PCCwTR?= NYrEWlJVW0GQR1XS
A101D NEHEcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fyd2lEPTB;M{KuOlIhdk1? M4XXTnNCVkeHUh?=
NMC-G1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKwTWM2OD1|Mz62O{BvVQ>? NGjIUoRUSU6JRWK=
LB1047-RCC NYmwclBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN2Lk[5JI5O NXzIcolXW0GQR1XS
EM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXTZ|hRUUN3ME2zPE42OyCwTR?= NWiwbndSW0GQR1XS
COLO-684 NHfQNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTN7Lkigcm0> NWC1OZpEW0GQR1XS
Becker NFzRTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n6dGlEPTB;NEGuNFUhdk1? MlvpV2FPT0WU
BL-41 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\5dmRKSzVyPUSzMlY3KG6P NEHlSm1USU6JRWK=
MDA-MB-134-VI M3XNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SzO2lEPTB;NESuNFIhdk1? MXfTRW5ITVJ?
L-363 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL5OHRKSzVyPUS0Mlc{KG6P MYLTRW5ITVJ?
ECC4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq4VGliUUN3ME20OE44QCCwTR?= M1:2WHNCVkeHUh?=
A388 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XzdWlEPTB;NESuPFIhdk1? NY[wcm8yW0GQR1XS
HEL NGj5WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR7Lke5JI5O MV3TRW5ITVJ?
RKO MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHTWJdKSzVyPUWwMlI6KG6P MXHTRW5ITVJ?
KINGS-1 NUnKfZNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vtbWlEPTB;NUGuOVUhdk1? NUfJToVSW0GQR1XS
EB-3 NE\LfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DQe2lEPTB;NUKuOlchdk1? M1O3RXNCVkeHUh?=
ARH-77 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF62THZKSzVyPUWyMlghdk1? MU\TRW5ITVJ?
GCIY NXTaUohuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LEW2lEPTB;NUOuOFYhdk1? NYrzbZhNW0GQR1XS
NCI-H1304 M13C[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrnTWM2OD13Nz6yNkBvVQ>? MYrTRW5ITVJ?
KARPAS-299 M{n6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTZzLkiyJI5O M3zGVnNCVkeHUh?=
IA-LM NES4c3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zVcWlEPTB;NkiuNVMhdk1? NFzYSHNUSU6JRWK=
GI-1 NITjSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XpbGlEPTB;N{CuN|khdk1? NGXJW2RUSU6JRWK=
TE-11 NUP0RXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljKTWM2OD15Nz6xO{BvVQ>? M2\MRnNCVkeHUh?=
LS-411N MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fWTWlEPTB;N{euOVchdk1? NWL2OoQyW0GQR1XS
no-11 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfGUoROUUN3ME24N{4zPCCwTR?= MknLV2FPT0WU
MV-4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL5eHZKSzVyPUizMlc{KG6P MXjTRW5ITVJ?
BV-173 NX\zPJFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTh|Lkm3JI5O NEf4N4JUSU6JRWK=
CMK M2\SZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjUNFlFUUN3ME24OE4yPiCwTR?= M2fVW3NCVkeHUh?=
LC4-1 NHP2fWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjKSlNLUUN3ME24Ok44OiCwTR?= MV3TRW5ITVJ?
COR-L279 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLWWFBiUUN3ME24O{4zPSCwTR?= MnuxV2FPT0WU
NCI-H209 NHzaNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTJUJhKSzVyPUi3MlQyKG6P MkDoV2FPT0WU
Raji M1TnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXVeZlOUUN3ME24PU44OiCwTR?= MWrTRW5ITVJ?
LB996-RCC M3PSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTl|LkSzJI5O NIXi[VNUSU6JRWK=
NCI-H526 NIjPfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLMTWM2OD17Mz61PUBvVQ>? M1jx[nNCVkeHUh?=
KGN M3m3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K5UGlEPTB;OU[uNlkhdk1? MV3TRW5ITVJ?
MOLT-4 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTl4Lke5JI5O MmfvV2FPT0WU
PF-382 NWfZe5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrzenJTUUN3ME25Ok44QSCwTR?= NFjPRpZUSU6JRWK=
BC-3 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;OPI1KSzVyPUm5MlE5KG6P MWDTRW5ITVJ?
KARPAS-422 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf4O2xKSzVyPUGwNk4xQSCwTR?= NFHYUoZUSU6JRWK=
SBC-1 M4PnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFyNz63OUBvVQ>? MlLyV2FPT0WU
LC-1F MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GzUmlEPTB;MUC4MlA2KG6P NGTmc29USU6JRWK=
GB-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfTZZpzUUN3ME2xNFkvODJibl2= Mn;EV2FPT0WU
SNB75 M2jYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ewTmlEPTB;MUG5MlY6KG6P MXHTRW5ITVJ?
BB65-RCC M3XFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFzOT65N{BvVQ>? MY\TRW5ITVJ?
NCI-N87 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF{MT65PEBvVQ>? M37xW3NCVkeHUh?=
IST-MEL1 NWTkUWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjZTWM2OD1zMkKuN|ghdk1? MXvTRW5ITVJ?
HOP-62 NHjJeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrLPIg1UUN3ME2xNlYvQDlibl2= MmXMV2FPT0WU
ACN Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF2Nj63OUBvVQ>? M3z2TnNCVkeHUh?=
DMS-114 M37UOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3POI1KSzVyPUG1NE43PyCwTR?= NFe1eJFUSU6JRWK=
MLMA M2DlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT0c|NRUUN3ME2xOVkvQDhibl2= NX6ySZFZW0GQR1XS
HT-144 NGi5UY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFThPFBKSzVyPUG2OU41OyCwTR?= MmXCV2FPT0WU
C2BBe1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7VcJhKSzVyPUG2O{44PiCwTR?= NV3p[VM6W0GQR1XS
L-428 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXjNVRlUUN3ME2xO|cvPyCwTR?= MVvTRW5ITVJ?
DU-4475 NUnJZoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfsV|dKSzVyPUG4O{43QCCwTR?= MVHTRW5ITVJ?
CP67-MEL NVyycIRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m1VWlEPTB;MUm5MlM5KG6P MY\TRW5ITVJ?
MEG-01 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\jTWM2OD1{MEGuPVYhdk1? NWewWoNRW0GQR1XS
IST-SL2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\4R3E4UUN3ME2yNFgvPjNibl2= MkHrV2FPT0WU
ES8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrKcY5KSzVyPUKyOU46PCCwTR?= MoP1V2FPT0WU
COLO-800 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPZTWFIUUN3ME2yN|UvOjhibl2= NEHLV3BUSU6JRWK=
MFH-ino M2\Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ|NT64OEBvVQ>? NG\W[GhUSU6JRWK=
OVCAR-4 M4PvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mzWGlEPTB;MkO3MlI1KG6P NXL2eYRlW0GQR1XS
PSN1 NH;4eYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD6TWM2OD1{NEKuO|Ehdk1? M4D3W3NCVkeHUh?=
EW-12 NGSzenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJ2Mz6xJI5O NXPacVFnW0GQR1XS
HCC1599 M1HWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHGbYRoUUN3ME2yOlEvPDdibl2= NECwUppUSU6JRWK=
SJSA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HwcWlEPTB;MkexMlQ3KG6P MkLCV2FPT0WU
ST486 NHXERlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD2TJlsUUN3ME2yPVYvOTRibl2= NGHmV4JUSU6JRWK=
NOMO-1 M1;4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;rOmsyUUN3ME2zNFAvOjFibl2= M37JRnNCVkeHUh?=
MN-60 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvObVBKSzVyPUOwOU4{OiCwTR?= MUjTRW5ITVJ?
HCC1187 NYfqZ3VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ETWM2OD1|MEeuNlUhdk1? NIDMWW5USU6JRWK=
SW982 NEPaVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vZ[GlEPTB;M{G0Mlc2KG6P MV7TRW5ITVJ?
LB647-SCLC NVPUUHo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjPXIxKSzVyPUOyPE44OSCwTR?= MonJV2FPT0WU
HC-1 M2Cx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fIcWlEPTB;M{O1MlUhdk1? NUHrNmN4W0GQR1XS
EHEB Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN|Nz61NkBvVQ>? MYTTRW5ITVJ?
TUR M1[zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOwTmpKSzVyPUO2N{46PSCwTR?= MoG2V2FPT0WU
LU-139 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y2WWlEPTB;M{e4MlAzKG6P Ml3pV2FPT0WU
NB1 NETsR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXx[|NKSzVyPUO4OE41PSCwTR?= MXrTRW5ITVJ?
BB30-HNC M33WVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPNWIhIUUN3ME2zPFgvOzJibl2= M3rReHNCVkeHUh?=
HAL-01 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTN6OT6yOkBvVQ>? NInWZZdUSU6JRWK=
K5 NX7CdIhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTjTWM2OD12MUGuN|chdk1? MYHTRW5ITVJ?
MZ2-MEL M1PLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRzMz62OEBvVQ>? M4HLW3NCVkeHUh?=
RXF393 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXjTWM2OD12MU[uOFUhdk1? NFfiXoxUSU6JRWK=
NCI-H1648 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorqTWM2OD12MUeuOVMhdk1? MVfTRW5ITVJ?
TE-12 NHfNUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[zSWlEPTB;NEO0MlI3KG6P MV7TRW5ITVJ?
EoL-1- MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTR|Nz65PEBvVQ>? MVnTRW5ITVJ?
JAR M{PLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTR|OD62NkBvVQ>? NELMTmNUSU6JRWK=
DSH1 NEXKOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHlTWM2OD12NUiuPVEhdk1? M2Lud3NCVkeHUh?=
NCI-H187 NHP3Z|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnOzTWM2OD12NkKuPFEhdk1? MWTTRW5ITVJ?
HCE-4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki0TWM2OD12N{euOlYhdk1? NH;Ld|RUSU6JRWK=
8-MG-BA NHu3[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHVTWM2OD13OEGuOVIhdk1? NHfCWXlUSU6JRWK=
KLE M33BcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHhTWM2OD13OEWuNkBvVQ>? M2nQNnNCVkeHUh?=
KNS-42 NILNeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DHOWlEPTB;NUi2MlgyKG6P NWnWcpA2W0GQR1XS
MSTO-211H M3n4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTZyOT63OEBvVQ>? M2TDTHNCVkeHUh?=
GDM-1 NITMfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7XTWM2OD14MUSuNFkhdk1? M4CwXnNCVkeHUh?=
TE-1 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nmfGlEPTB;NkS2MlEzKG6P Mkn6V2FPT0WU
BT-474 NYK1R5lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XOb2lEPTB;NkS3MlA3KG6P MVnTRW5ITVJ?
KARPAS-45 M4DTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvmc2tbUUN3ME22OFcvPiCwTR?= NI\OO29USU6JRWK=
MOLT-16 MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[xT2lEPTB;NkS3Mlk{KG6P NFfSNpdUSU6JRWK=
KURAMOCHI NEnUOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n5SGlEPTB;NkW3MlUyKG6P M1fRd3NCVkeHUh?=
K-562 NWrlUnE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVey[YFtUUN3ME22OlkvPTFibl2= MoDDV2FPT0WU
EKVX MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\FTWM2OD14N{KuO|Ehdk1? NFrBZYNUSU6JRWK=
GAK NUXGWld5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[xTG1GUUN3ME22O|UvOyCwTR?= MnHLV2FPT0WU
NCI-SNU-5 NUL1R3JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq3dXJKSzVyPU[5NE4xOSCwTR?= NXfBO3E3W0GQR1XS
NCI-H2126 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDFe4ZNUUN3ME23NlYvQDdibl2= MlHLV2FPT0WU
CTV-1 MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWThRWZiUUN3ME23OFQvQSCwTR?= MnzhV2FPT0WU
SW962 MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn61TWM2OD15NEiuOFQhdk1? MXfTRW5ITVJ?
MONO-MAC-6 NInNUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTd3Nj65N{BvVQ>? MYTTRW5ITVJ?
NCI-H748 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDHTWM2OD15NUiuPVkhdk1? NEKxVoZUSU6JRWK=
NCI-H524 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjLTWM2OD15OECuO|Mhdk1? Mle4V2FPT0WU
LS-123 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTd7NT62PUBvVQ>? M2T4d3NCVkeHUh?=
NB7 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLzdXNOUUN3ME24NVQvOTRibl2= MYfTRW5ITVJ?
LS-1034 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPl[GdKSzVyPUiyPE46QCCwTR?= NV;XRlYzW0GQR1XS
TE-5 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\md2lEPTB;OEizMlU3KG6P NEjGRo5USU6JRWK=
A704 NYCyR2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILXOZBKSzVyPUi5PU4yPSCwTR?= MVTTRW5ITVJ?
TK10 NGX2WWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX5b5ZvUUN3ME25NVYvODNibl2= MYTTRW5ITVJ?
NCI-H345 M4fFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHCTWM2OD17NEOuNlIhdk1? Ml21V2FPT0WU
CGTH-W-1 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\3TWM2OD17NEiuNVMhdk1? M2G0VnNCVkeHUh?=
NCI-H510A MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n2SWlEPTB;OUi1MlEzKG6P NIXPcWdUSU6JRWK=
NCI-H1963 NG\IN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfDTWM2OD1zLkCzNlkzKM7:TR?= NWr2U2V2W0GQR1XS
SCC-3 M3vXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHIcnFKSzVyPUGuNFM1OTRizszN MlO1V2FPT0WU
EW-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\RbHBnUUN3ME2xMlA5PzR|IN88US=> MUTTRW5ITVJ?
CPC-N Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwMEi4JO69VQ>? MX3TRW5ITVJ?
NCI-H1417 NFfUXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXheIRpUUN3ME2xMlEzOjZizszN MUXTRW5ITVJ?
DG-75 NFHhUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjuUWhtUUN3ME2xMlE3Ojh3IN88US=> Mn;zV2FPT0WU
HD-MY-Z NYLWfHNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLITWM2OD1zLkG2OFE3KM7:TR?= NX3qZ4p6W0GQR1XS
ATN-1 M4L5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH5TWM2OD1zLkK2NlA6KM7:TR?= M2TBR3NCVkeHUh?=
KM-H2 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DySmlEPTB;MT6yOlQxQCEQvF2= M2DvUnNCVkeHUh?=
NCI-H2081 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXoTWM2OD1zLkK2OlM4KM7:TR?= NVXlOo5VW0GQR1XS
HL-60 NWPKbmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrxTWM2OD1zLkK2PVU6KM7:TR?= MWfTRW5ITVJ?
DB NHn0O3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwMkeyOFIh|ryP Mmn1V2FPT0WU
NCI-H1522 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLOcYRWUUN3ME2xMlI5QDh5IN88US=> MnHYV2FPT0WU
AM-38 NVLabHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e4c2lEPTB;MT6zNFczKM7:TR?= MnrVV2FPT0WU
NCI-H446 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknKTWM2OD1zLkOyNVIyKM7:TR?= NVHWXnk{W0GQR1XS
SU-DHL-1 NWjQcmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLPTWM2OD1zLkOyPFAyKM7:TR?= NWWzbZlXW0GQR1XS
NH-12 NFLwSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPyTWM2OD1zLkO2N|c1KM7:TR?= MVTTRW5ITVJ?
DMS-79 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L4WWlEPTB;MT6zOlg3PiEQvF2= NE[xb|JUSU6JRWK=
NCI-H716 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;iWI5lUUN3ME2xMlM5QTh4IN88US=> NIjZb|lUSU6JRWK=
ML-2 NWPzV2JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnEbmpuUUN3ME2xMlQyPTJ7IN88US=> MnGzV2FPT0WU
NB10 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zpb2lEPTB;MT60OlY{OiEQvF2= NXTjdWJ{W0GQR1XS
ONS-76 NWnPclR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzBTWM2OD1zLkWzOVY6KM7:TR?= NXHTZmNIW0GQR1XS
LOUCY M1;aVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT5TWM2OD1zLkW0OlU4KM7:TR?= MoPPV2FPT0WU
SCLC-21H MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3FO5FKSzVyPUGuOVg2QDJizszN MXTTRW5ITVJ?
TGW MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwNkO5O|Uh|ryP MVXTRW5ITVJ?
LXF-289 NH3BVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ERYlKSzVyPUGuO|MzPjhizszN MXPTRW5ITVJ?
BB49-HNC M{PHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwN{O1PFYh|ryP M1PzZnNCVkeHUh?=
NCI-H747 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrWZ4dKSzVyPUGuO|U{PDZizszN NIWz[HlUSU6JRWK=
LU-165 NVn4XoxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwOES5PFYh|ryP MmrhV2FPT0WU
OMC-1 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnGcGlKSzVyPUGuPVUxPjZizszN NF3F[4VUSU6JRWK=
RCC10RGB MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3UVGZuUUN3ME2xMlk2QDF5IN88US=> M1jBdnNCVkeHUh?=
SW684 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TJc2lEPTB;MT65OlA6QSEQvF2= NXn4UVJGW0GQR1XS
TE-8 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nOfGlEPTB;Mj6wOVU2QSEQvF2= M3HoOXNCVkeHUh?=
SK-N-DZ M2\KNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fBe2lEPTB;Mj6xN|I4PCEQvF2= NUPzXmJ5W0GQR1XS
EVSA-T MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJwMUezNVUh|ryP NEnhVYpUSU6JRWK=
KASUMI-1 NYfxUpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHpTJVKSzVyPUKuNVg5OTVizszN MYLTRW5ITVJ?
NKM-1 NGTyb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTNTWM2OD1{LkK1OFczKM7:TR?= MV;TRW5ITVJ?
CAL-148 NHrDdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfXWWpKSzVyPUKuN|M3OTRizszN Mn3KV2FPT0WU
NCI-H64 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17NTGlEPTB;Mj6zOFI{OiEQvF2= NEnmUGZUSU6JRWK=
KNS-81-FD NXqzZphYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDtSYhGUUN3ME2yMlM3PjJizszN NGPoUYVUSU6JRWK=
KM12 NYjZXJpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWzTWM2OD1{LkSwPFM6KM7:TR?= MmOzV2FPT0WU
SW954 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwNEe3O|kh|ryP MXXTRW5ITVJ?
NCI-H1395 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DyTmlEPTB;Mj61NlY1PSEQvF2= M1G0NHNCVkeHUh?=
DJM-1 NXHre2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fY[2lEPTB;Mj62NFY{KM7:TR?= M{W5U3NCVkeHUh?=
COLO-668 MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TG[2lEPTB;Mj64NlY6PSEQvF2= M3;afXNCVkeHUh?=
NCI-H1436 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPYW3FKSzVyPUKuPFU3OTVizszN MmWwV2FPT0WU
LB2241-RCC NFvndoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPtb|ZQUUN3ME2yMlg3QDN7IN88US=> NVH1dIxUW0GQR1XS
GT3TKB MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzWRVVzUUN3ME2yMlg6ODV3IN88US=> NFfL[FhUSU6JRWK=
COLO-824 M{jXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1znSmlEPTB;Mj64PVc3QCEQvF2= Mk\VV2FPT0WU
ES1 NFq1S5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qyeWlEPTB;Mj64PVg4QSEQvF2= MWXTRW5ITVJ?
LB771-HNC NXjDfYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK3eFhUUUN3ME2yMlkxQTR4IN88US=> NGWxR3VUSU6JRWK=
GI-ME-N M3rLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3GXpRKSzVyPUOuNFA6ODRizszN MkKzV2FPT0WU
NALM-6 NV:1VHFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r1eWlEPTB;Mz6wNFk{OyEQvF2= M4PqNnNCVkeHUh?=
LU-134-A Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHv[2dKSzVyPUOuNFU1OjVizszN NFLKOWNUSU6JRWK=
DMS-153 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwMEW4NlQh|ryP NH7IemZUSU6JRWK=
MZ1-PC M{C0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwMEmwO|gh|ryP MVrTRW5ITVJ?
NCI-H1155 NYO5TnhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT3W3JOUUN3ME2zMlEyPjFizszN MmXRV2FPT0WU
CAS-1 NVXu[3RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PiXWlEPTB;Mz6xN|cxPyEQvF2= NGrUWllUSU6JRWK=
D-502MG NWXmb4pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnO[YVtUUN3ME2zMlE1OzlizszN NH;jVo1USU6JRWK=
NCI-H2141 M3;i[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfPTWM2OD1|LkG3OFUzKM7:TR?= M3rCZ3NCVkeHUh?=
NB6 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;XXFR4UUN3ME2zMlE5OjV7IN88US=> M13H[nNCVkeHUh?=
NCCIT NHj1S2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwMkG4NFkh|ryP NI\6eHBUSU6JRWK=
NB69 M4HhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPpfnZZUUN3ME2zMlMyQDlzIN88US=> MX;TRW5ITVJ?
JVM-2 NYTheXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNwM{[0N|Mh|ryP MYHTRW5ITVJ?
K052 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfqUmxuUUN3ME2zMlM4QTZ6IN88US=> NX\X[HRoW0GQR1XS
HCC2157 M3;XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\DWW1KSzVyPUOuOVMzOjhizszN M3nWfXNCVkeHUh?=
KMOE-2 NIrrflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwNUSyOFIh|ryP NWTB[WNVW0GQR1XS
SF268 MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P0VmlEPTB;Mz63NVU2PCEQvF2= NV\LWYpGW0GQR1XS
CHP-126 NWXPZ3pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzRb45KSzVyPUOuO|Y1PThizszN MofWV2FPT0WU
CP66-MEL NXPHXmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XHSGlEPTB;Mz63PVA6PCEQvF2= MVzTRW5ITVJ?
NCI-H69 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTRwMEG5N|Yh|ryP MWrTRW5ITVJ?
A253 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;TZWxkUUN3ME20MlAzOTBzIN88US=> Mnq3V2FPT0WU
NB14 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPwNW5EUUN3ME20MlExPDd7IN88US=> M1HxRXNCVkeHUh?=
NCI-H1694 NFjpNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LiZWlEPTB;ND6xN|EyOiEQvF2= MWnTRW5ITVJ?
NCI-H2196 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTRwMUexOlkh|ryP NVTwdXVEW0GQR1XS
TE-9 NXzK[2tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHUdlJvUUN3ME20MlE4PTh{IN88US=> NUOzd3ZNW0GQR1XS
D-283MED M3;pT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPabGZsUUN3ME20MlE5QDRizszN MVrTRW5ITVJ?
OCI-AML2 M{HlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRwMUm0PFkh|ryP NWP3OohsW0GQR1XS
D-263MG M{LsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD2SnNRUUN3ME20MlIzQTZzIN88US=> MWnTRW5ITVJ?
MPP-89 M1jNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRwMkezNFQh|ryP M1r3VHNCVkeHUh?=
LAMA-84 NHjEeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTRwM{C0NlEh|ryP MXrTRW5ITVJ?
LB373-MEL-D MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zuZWlEPTB;ND6zOlc5QSEQvF2= NHT0ToZUSU6JRWK=
UACC-257 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwM{m1N|Qh|ryP MVHTRW5ITVJ?
MC-CAR M3vTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH4XY0yUUN3ME20MlQ{QTlizszN M331SXNCVkeHUh?=
COLO-320-HSR MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTRwNES0Nlch|ryP NVfab4JJW0GQR1XS
P30-OHK NF;rWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjnPHFKSzVyPUSuOlY2QDFizszN MoLBV2FPT0WU
UACC-812 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrmR2xKSzVyPUSuOlkyPjFizszN NVzNcXZrW0GQR1XS
CTB-1 NXL6OYNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPSTWM2OD12LkexOVU2KM7:TR?= M{izNXNCVkeHUh?=
ALL-PO MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki3TWM2OD12Lki0NFc4KM7:TR?= NWDofmV4W0GQR1XS
SK-MEL-2 NEPDUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXPXnl7UUN3ME20Mlg3QTV3IN88US=> MUnTRW5ITVJ?
TC-YIK M4rseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofNTWM2OD12Lkm3PVQzKM7:TR?= MXzTRW5ITVJ?
NCI-H1882 M4Lk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTVwMEKwNFEh|ryP NHjiRYJUSU6JRWK=
MHH-CALL-2 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKwS4VKSzVyPUWuNFUxPDJizszN M3rtTHNCVkeHUh?=
U-87-MG NUfmc5pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH2UWZKSzVyPUWuNFk1PjZizszN MlfyV2FPT0WU
NCI-H1092 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\WTWM2OD13LkK2OVU2KM7:TR?= NW[wbopYW0GQR1XS
TE-441-T NUX2[VdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml64TWM2OD13LkK3PFIh|ryP NUnGR2JvW0GQR1XS
SK-MEL-1 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLSTWM2OD13LkK5NFQ1KM7:TR?= MYjTRW5ITVJ?
EW-22 NUHUVpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXFTWM2OD13LkK5OFY3KM7:TR?= MkXFV2FPT0WU
MZ7-mel NWLpXFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPmTWM2OD13LkSwOlkyKM7:TR?= NInoS2xUSU6JRWK=
LP-1 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq3NZNNUUN3ME21MlQyOjlzIN88US=> NEXNSIhUSU6JRWK=
NCI-SNU-16 M2\XWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PY[GlEPTB;NT62OFA4PCEQvF2= Mkj3V2FPT0WU
LU-65 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXZZ5hKSzVyPUWuO|Y{PzNizszN NWHBeGlZW0GQR1XS
CW-2 M2rt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO0b2ROUUN3ME21Mlg2QTV7IN88US=> NEHIWlhUSU6JRWK=
WSU-NHL NH20UnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fqdWlEPTB;NT65OVE4PCEQvF2= M4LzXnNCVkeHUh?=
IST-MES1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fOV2lEPTB;NT65OVQ1OyEQvF2= MX\TRW5ITVJ?
U-266 NEj1fllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPTbVFKSzVyPUWuPVgzODJizszN M{DyW3NCVkeHUh?=
TALL-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M325Z2lEPTB;Nj6xOFY5QCEQvF2= Mk\oV2FPT0WU
Calu-6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqwTWM2OD14LkG1N|E3KM7:TR?= Mmj2V2FPT0WU
MMAC-SF MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfxPJZzUUN3ME22MlE5PTV4IN88US=> NF\L[mZUSU6JRWK=
NCI-H82 M3HUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZwMkC0PFkh|ryP MmLHV2FPT0WU
RS4-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3BUZU{UUN3ME22MlI2QDl5IN88US=> M3PxTnNCVkeHUh?=
SNU-C2B NUKxWIN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nTdWlEPTB;Nj60NFk3QSEQvF2= NX7keG9WW0GQR1XS
BOKU MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;HTWM2OD14LkS3OVk4KM7:TR?= MX3TRW5ITVJ?
C8166 M3fwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXoN3ZDUUN3ME22MlU2QTF{IN88US=> NGjSeGxUSU6JRWK=
D-247MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\kfmlEPTB;Nz6wOFM1PyEQvF2= M2HMWHNCVkeHUh?=
EW-18 NGHYUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTdwMEeyPVIh|ryP NXLNUYxDW0GQR1XS
KG-1 M{PzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfabVRKSzVyPUeuOlI4OzhizszN NUXzN2FyW0GQR1XS
REH Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHSSHBKSzVyPUeuOlgyODlizszN MXHTRW5ITVJ?
U-698-M NUi2O5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTdwOESzNVUh|ryP NXX2UoFlW0GQR1XS
KP-N-RT-BM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3CRVh1UUN3ME23Mlk{ODJ7IN88US=> M{\wfHNCVkeHUh?=
MS-1 NYPkb2xFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTQ[GxKSzVyPUeuPVYxPDFizszN M3vhXnNCVkeHUh?=
SNU-C1 M{nPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPSRoZbUUN3ME23Mlk5OTl{IN88US=> M{LxU3NCVkeHUh?=
SK-MM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjwOph5UUN3ME24MlI3ODZ3IN88US=> MV3TRW5ITVJ?
LAN-6 NVn1Uos1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV60bpM3UUN3ME24MlMxODBzIN88US=> M1S1bHNCVkeHUh?=
NEC8 NGH1d4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn2XYpNUUN3ME24MlMxPjlzIN88US=> MknjV2FPT0WU
NCI-H1770 NUO3XIV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\3UnRXUUN3ME24MlM5ODB{IN88US=> MnjSV2FPT0WU
D-336MG NH:0VoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fDSGlEPTB;OD60NFEyPiEQvF2= NIO2UoVUSU6JRWK=
COLO-829 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn71TWM2OD16LkS4PFc6KM7:TR?= MX\TRW5ITVJ?
LS-513 NXi4SFR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[zcHVKSzVyPUiuOVk2QTlizszN NUnS[FU1W0GQR1XS
YT NI\EUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLXTWM2OD16Lk[yOFI4KM7:TR?= MXnTRW5ITVJ?
EW-24 NWHZTVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LtXGlEPTB;OD63OlU1KM7:TR?= MUTTRW5ITVJ?
IST-SL1 NY[xNJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTlb4h{UUN3ME24Mlg3PTR|IN88US=> MV;TRW5ITVJ?
CA46 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRThwOUWwPVgh|ryP NFriTIdUSU6JRWK=
NCI-H1838 M4nDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\sS2lEPTB;OD65PFYxOiEQvF2= NYqwdphSW0GQR1XS
NCI-H719 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULOTVI3UUN3ME25MlI2Ojd7IN88US=> M4nwNnNCVkeHUh?=
HCE-T MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS0TWM2OD17LkOwPFUyKM7:TR?= NUDTPIliW0GQR1XS
A498 M1rV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTlwM{[xNlQh|ryP NVLaU5FWW0GQR1XS
LB831-BLC NVOyZ4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L2T2lEPTB;OT63OlUzOSEQvF2= MYfTRW5ITVJ?
SKM-1 NYnScoJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTlwOEW5OlMh|ryP MnroV2FPT0WU
THP-1 M2r6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TLTWlEPTB;OT65OlkyQCEQvF2= MU\TRW5ITVJ?
SHP-77 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfDXWR6UUN3ME2xNE41ODdizszN M3W1N3NCVkeHUh?=
EW-3 M3e2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfsTWM2OD1zMD62Nlg6KM7:TR?= Mn;oV2FPT0WU
KY821 NFzGRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;nR4RKSzVyPUGwMlc3OyEQvF2= NUfaSm9UW0GQR1XS
NCI-SNU-1 NFPE[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DVRWlEPTB;MUGuNFIyPyEQvF2= MYrTRW5ITVJ?
HCC2218 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\Wbos3UUN3ME2xNU4{QTh4IN88US=> NW\ocWhVW0GQR1XS
IM-9 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFzLkWxNFYh|ryP MVzTRW5ITVJ?
NCI-H889 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFzLkWzNVMh|ryP NUnTTHNwW0GQR1XS
HDLM-2 M1vIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorNTWM2OD1zMj60NVU6KM7:TR?= NWHuV4FKW0GQR1XS
LB2518-MEL NWPhdI5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e5XmlEPTB;MUKuOlgyPSEQvF2= MVTTRW5ITVJ?
NCI-H23 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3mO|lKSzVyPUGzMlI1OjVizszN MorJV2FPT0WU
NB17 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfITGZKSzVyPUGzMlQ2PzlizszN NGjBco5USU6JRWK=
NCI-H322M M{\kfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorlTWM2OD1zND60NFY5KM7:TR?= MoPtV2FPT0WU
SUP-T1 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTXTWM2OD1zND60NVMh|ryP M3WwN3NCVkeHUh?=
ES3 M3HYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF3LkC3NFMh|ryP NX7ZVXBHW0GQR1XS
ES5 NXLY[YtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF3LkC3PFch|ryP NIXJc4dUSU6JRWK=
NCI-H1650 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;1W|lKSzVyPUG1MlQ6PzlizszN MXXTRW5ITVJ?
NCI-H226 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnniTWM2OD1zNT64O|Y5KM7:TR?= NVO5UGg{W0GQR1XS
COR-L88 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF4LkOxOEDPxE1? M{PMenNCVkeHUh?=
SCC-15 NUi1OXhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HQdGlEPTB;MU[uN|g3QSEQvF2= MYHTRW5ITVJ?
GOTO M{DX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTYTWM2OD1zNj60O|k{KM7:TR?= MWDTRW5ITVJ?
SIMA MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTSTWM2OD1zNj60PFAzKM7:TR?= M{PrWXNCVkeHUh?=
NCI-H1299 M{n4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTFe21KSzVyPUG3MlE2QTFizszN NWnlTWtMW0GQR1XS
NCI-H1581 M2XWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGzTWM2OD1zNz60NlE6KM7:TR?= NHLLb2VUSU6JRWK=
MHH-NB-11 M4TTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7QfItpUUN3ME2xO{46Pjh|IN88US=> NGjPRllUSU6JRWK=
MFM-223 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\G[4dyUUN3ME2xPE4xPTN6IN88US=> MlrGV2FPT0WU
ES7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjHdYQyUUN3ME2xPE42PDNzIN88US=> M3nld3NCVkeHUh?=
JVM-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HhTWlEPTB;MUiuO|E4KM7:TR?= NV\qWVYxW0GQR1XS
RL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjPeo1sUUN3ME2yNE4{QDhizszN NET3N4hUSU6JRWK=
EC-GI-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJzLkKwOFEh|ryP NIrte3JUSU6JRWK=
LNCaP-Clone-FGC Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn4eVFKSzVyPUKxMlY4PjhizszN M1zZfnNCVkeHUh?=
IMR-5 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LtR2lEPTB;MkGuPFQ6PCEQvF2= MWHTRW5ITVJ?
KP-N-YS NFzONpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlryTWM2OD1{MT64O|Uh|ryP NHPu[IFUSU6JRWK=
Mo-T MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:yS2lEPTB;MkKuNlE5PSEQvF2= M4SzTHNCVkeHUh?=
NCI-H128 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PFcGlEPTB;MkOuOVg2OyEQvF2= NGTseGlUSU6JRWK=
RH-1 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjOTZNKSzVyPUKzMlc5PjZizszN M4myNHNCVkeHUh?=
NCI-H2171 M4XaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HQbWlEPTB;MkSuNlQ5PSEQvF2= NX3SUodrW0GQR1XS
RPMI-8866 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvyTWM2OD1{Nj63OFIh|ryP MnHiV2FPT0WU
SK-N-FI NE\nUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojlTWM2OD1{Nz6zPFEyKM7:TR?= MXLTRW5ITVJ?
LOXIMVI MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7qVo5WUUN3ME2yO{45ODVzIN88US=> NH;z[WlUSU6JRWK=
P31-FUJ MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrtbZZrUUN3ME2zNU42Ozd2IN88US=> NF;BZ|dUSU6JRWK=
KMS-12-PE NXjHbnFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTh[Jl3UUN3ME20PU42OzB{IN88US=> M3LYVXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ